Publications
2024
Reconsidering the Role of Isoniazid in Drug-Resistant Tuberculosis.
Davies, G. R. (2024). Reconsidering the Role of Isoniazid in Drug-Resistant Tuberculosis.. American journal of respiratory and critical care medicine, 210(3), 257-259. doi:10.1164/rccm.202403-0628ed
Analysis of time-to-positivity data in tuberculosis treatment studies: Identifying a new limit of quantification.
2023
Determining the minimum duration of treatment in tuberculosis: An order restricted non-inferiority trial design
Serra, A., Mozgunov, P., Davies, G., & Jaki, T. (2023). Determining the minimum duration of treatment in tuberculosis: An order restricted non-inferiority trial design. PHARMACEUTICAL STATISTICS. doi:10.1002/pst.2320
Update on drug treatments for multidrug resistant tuberculosis
Davies, G. R., & Aston, S. (2023). Update on drug treatments for multidrug resistant tuberculosis. CURRENT OPINION IN INFECTIOUS DISEASES, 36(2), 132-139. doi:10.1097/QCO.0000000000000899
2022
Determination of the Pharmacokinetics and Pharmacodynamics of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol in a Cross-Over Cynomolgus Macaque Model of <i>Mycobacterium tuberculosis</i> Infection
Sibley, L., White, A. D., Sarfas, C., Gullick, J., Gleeson, F., Lanni, F., . . . Sharpe, S. (2022). Determination of the Pharmacokinetics and Pharmacodynamics of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol in a Cross-Over Cynomolgus Macaque Model of <i>Mycobacterium tuberculosis</i> Infection. PHARMACEUTICS, 14(12). doi:10.3390/pharmaceutics14122666
Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis.
Gafar, F., Wasmann, R. E., McIlleron, H. M., Aarnoutse, R. E., Schaaf, H. S., Marais, B. J., . . . Global Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in Pharmacokinetics of Anti-TB Drugs. (2022). Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis.. The European respiratory journal, 2201596. doi:10.1183/13993003.01596-2022
High Intrapulmonary Rifampicin and Isoniazid Concentrations Are Associated With Rapid Sputum Bacillary Clearance in Patients With Pulmonary Tuberculosis
McCallum, A. D., Pertinez, H. E., Chirambo, A. P., Sheha, I., Chasweka, M., Malamba, R., . . . Mwandumba, H. C. (2022). High Intrapulmonary Rifampicin and Isoniazid Concentrations Are Associated With Rapid Sputum Bacillary Clearance in Patients With Pulmonary Tuberculosis. CLINICAL INFECTIOUS DISEASES, 75(9), 1520-1528. doi:10.1093/cid/ciac228
Clinical features and management of human monkeypox: a retrospective observational study in the UK
Adler, H., Gould, S., Hine, P., Snell, L. B., Wong, W., Houlihan, C. F., . . . Price, N. M. (2022). Clinical features and management of human monkeypox: a retrospective observational study in the UK. LANCET INFECTIOUS DISEASES, 22(8), 1153-1162. doi:10.1016/S1473-3099(22)00228-6
Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin
Pillay, S., Steingart, K. R., Davies, G. R., Chaplin, M., De Vos, M., Schumacher, S. G., . . . Theron, G. (2022). Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (5). doi:10.1002/14651858.CD014841.pub2
Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer A Systematic Review and Meta-analysis
Khoury, E., Nevitt, S., Madsen, W. R., Turtle, L., Davies, G., & Palmieri, C. (2022). Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer A Systematic Review and Meta-analysis. JAMA NETWORK OPEN, 5(5). doi:10.1001/jamanetworkopen.2022.10880
Population pharmacokinetics of ethambutol in African children: a pooled analysis
Tikiso, T., McIlleron, H., Abdelwahab, M. T., Bekker, A., Hesseling, A., Chabala, C., . . . Denti, P. (2022). Population pharmacokinetics of ethambutol in African children: a pooled analysis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(7), 1949-1959. doi:10.1093/jac/dkac127
Serial measurement of <i>M. tuberculosis</i> in blood from critically-ill patients with HIV-associated tuberculosis
Barr, D. A., Schutz, C., Balfour, A., Shey, M., Kamariza, M., Bertozzi, C. R., . . . Davies, G. (2022). Serial measurement of <i>M. tuberculosis</i> in blood from critically-ill patients with HIV-associated tuberculosis. EBIOMEDICINE, 78. doi:10.1016/j.ebiom.2022.103949
Social and health factors associated with adverse treatment outcomes among people with multidrug-resistant tuberculosis in Sierra Leone: a national, retrospective cohort study
Kamara, R. F., Saunders, M. J., Sahr, F., Losa-Garcia, J. E., Foray, L., Davies, G., & Wingfield, T. (2022). Social and health factors associated with adverse treatment outcomes among people with multidrug-resistant tuberculosis in Sierra Leone: a national, retrospective cohort study. LANCET GLOBAL HEALTH, 10(4), E543-E554. Retrieved from https://www.webofscience.com/
Mouse models of Japanese encephalitis virus infection: A systematic review and meta-analysis using a meta-regression approach.
Bharucha, T., Cleary, B., Farmiloe, A., Sutton, E., Hayati, H., Kirkwood, P., . . . Turtle, L. (2022). Mouse models of Japanese encephalitis virus infection: A systematic review and meta-analysis using a meta-regression approach.. PLoS neglected tropical diseases, 16(2), e0010116. doi:10.1371/journal.pntd.0010116
2021
The Treatment of Tuberculosis
Peloquin, C. A., & Davies, G. R. (2021). The Treatment of Tuberculosis. CLINICAL PHARMACOLOGY & THERAPEUTICS, 110(6), 1455-1466. doi:10.1002/cpt.2261
Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis
McCallum, A. D., Pertinez, H. E., Else, L. J., Dilly-Penchala, S., Chirambo, A. P., Sheha, I., . . . Mwandumba, H. C. (2021). Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis. CLINICAL INFECTIOUS DISEASES, 73(9), E3365-E3373. doi:10.1093/cid/ciaa1265
Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study
Denti, P., Wasmann, R. E., van Rie, A., Winckler, J., Bekker, A., Rabie, H., . . . McIlleron, H. M. (2021). Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study. CLINICAL INFECTIOUS DISEASES, 75(1), 141-151. doi:10.1093/cid/ciab908
Flow cytometry method for absolute counting and single-cell phenotyping of mycobacteria
Barr, D. A., Omollo, C., Mason, M., Koch, A., Wilkinson, R. J., Lalloo, D. G., . . . Davies, G. (2021). Flow cytometry method for absolute counting and single-cell phenotyping of mycobacteria. SCIENTIFIC REPORTS, 11(1). doi:10.1038/s41598-021-98176-5
Population pharmacokinetics and pharmacodynamics of investigational regimens' drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial
Nyang'wa, B. -T., Kloprogge, F., Moore, D. A. J., Bustinduy, A., Motta, I., Berry, C., & Davies, G. R. (2021). Population pharmacokinetics and pharmacodynamics of investigational regimens' drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial. BMJ OPEN, 11(9). doi:10.1136/bmjopen-2020-047185
Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin
Pillay, S., Davies, G. R., Chaplin, M., De Vos, M., Schumacher, S. G., Warren, R., . . . Theron, G. (n.d.). Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin. Cochrane Database of Systematic Reviews, 2021(6). doi:10.1002/14651858.cd014841
Flow cytometry method for absolute counting and single-cell phenotyping of mycobacteria
Barr, D., Omollo, C., Mason, M., Koch, A., Wilkinson, R., Lalloo, D., . . . Davies, G. (2021). Flow cytometry method for absolute counting and single-cell phenotyping of mycobacteria. doi:10.1101/2021.05.01.442251
The potential of microdialysis to estimate rifampicin concentrations in the lung of guinea pigs
Lanni, F., Burton, N., Harris, D., Fotheringham, S., Clark, S., Skinner, O., . . . Williams, A. (2021). The potential of microdialysis to estimate rifampicin concentrations in the lung of guinea pigs. PLOS ONE, 16(1). doi:10.1371/journal.pone.0245922
2020
Characterization of DNA methylation in Malawian <i>Mycobacterium tuberculosis</i> clinical isolates
Ndhlovu, V., Kiran, A., Sloan, D. J., Mandala, W., Nliwasa, M., Everett, D. B., . . . Davies, G. (2020). Characterization of DNA methylation in Malawian <i>Mycobacterium tuberculosis</i> clinical isolates. PEERJ, 8. doi:10.7717/peerj.10432
Consensus-based antimicrobial resistance and stewardship competencies for UK undergraduate medical students
McMaster, D., Courtenay, M., Santucci, C., Davies, A. P., Kirby, A., Seddon, O., . . . Patel, S. (2020). Consensus-based antimicrobial resistance and stewardship competencies for UK undergraduate medical students. JAC-ANTIMICROBIAL RESISTANCE, 2(4). doi:10.1093/jacamr/dlaa096
STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline
Chaplin, M., Kirkham, J. J., Dwan, K., Sloan, D. J., Davies, G., & Jorgensen, A. L. (2020). STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline. PLOS MEDICINE, 17(9). doi:10.1371/journal.pmed.1003344
Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis
Kloprogge, F., Mwandumba, H. C., Banda, G., Kamdolozi, M., Shani, D., Corbett, E. L., . . . Sloan, D. J. (2020). Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis. OPEN FORUM INFECTIOUS DISEASES, 7(7). doi:10.1093/ofid/ofaa218
Mycobacterium tuberculosis bloodstream infection prevalence, diagnosis, and mortality risk in seriously ill adults with HIV: a systematic review and meta-analysis of individual patient data
Barr, D. A., Lewis, J. M., Feasey, N., Schutz, C., Kerkhoff, A. D., Jacob, S. T., . . . Meintjes, G. (n.d.). Mycobacterium tuberculosis bloodstream infection prevalence, diagnosis, and mortality risk in seriously ill adults with HIV: a systematic review and meta-analysis of individual patient data. The Lancet Infectious Diseases. doi:10.1016/S1473-3099(19)30695-4
Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load Assay
Sabiiti, W., Azam, K., Farmer, E. C. W., Kuchaka, D., Mtafya, B., Bowness, R., . . . Gillespie, S. H. (2020). Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load Assay. THORAX, 75(7), 606-608. doi:10.1136/thoraxjnl-2019-214238
Delivery of long-term-injectable agents for TB by lay carers: pragmatic randomised trial
Cohen, D. B., Mbendera, K., Maheswaran, H., Mukaka, M., Mangochi, H., Phiri, L., . . . Squire, B. (2020). Delivery of long-term-injectable agents for TB by lay carers: pragmatic randomised trial. THORAX, 75(1), 64-71. doi:10.1136/thoraxjnl-2018-212675
TB control programmes remain an important gateway to HIV diagnosis in the era of expanded access to HIV care
McCallum, A. D., Sheha, I., Chasweka, M., Banda, G., Davies, G. R., Khoo, S. H., . . . Sloan, D. J. (2020). TB control programmes remain an important gateway to HIV diagnosis in the era of expanded access to HIV care. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 24(1), 131-132. doi:10.5588/ijtld.19.0504
2019
The impact of inclusion, dose and duration of pyrazinamide (PZA) on efficacy and safety outcomes in tuberculosis: systematic review and meta-analysis protocol
Millard, J. D., Mackay, E. A., Bonnett, L. J., & Davies, G. R. (2019). The impact of inclusion, dose and duration of pyrazinamide (PZA) on efficacy and safety outcomes in tuberculosis: systematic review and meta-analysis protocol. SYSTEMATIC REVIEWS, 8(1). doi:10.1186/s13643-019-1231-1
Genetic diversity of <i>Mycobacterium tuberculosis</i> clinical isolates in Blantyre, Malawi
Ndhlovu, V., Kiran, A., Sloan, D., Mandala, W., Kontogianni, K., Kamdolozi, M., . . . Davies, G. (2019). Genetic diversity of <i>Mycobacterium tuberculosis</i> clinical isolates in Blantyre, Malawi. HELIYON, 5(10). doi:10.1016/j.heliyon.2019.e02638
Protocol for the development of the STrengthening the Reporting Of Pharmacogenetic Studies (STROPS) guideline: checklist of items for reporting pharmacogenetic studies
Richardson, M., Kirkham, J. J., Dwan, K. M., Sloan, D. J., Davies, G., & Jorgensen, A. (2019). Protocol for the development of the STrengthening the Reporting Of Pharmacogenetic Studies (STROPS) guideline: checklist of items for reporting pharmacogenetic studies. BMJ OPEN, 9(7). doi:10.1136/bmjopen-2019-030212
Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs
Davies, G., Boeree, M., Hermann, D., & Hoelscher, M. (2019). Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs. PLOS MEDICINE, 16(7). doi:10.1371/journal.pmed.1002851
Bedaquiline kills persistent <i>Mycobacterium tuberculosis</i> with no disease relapse: an <i>in vivo</i> model of a potential cure
Hu, Y., Pertinez, H., Liu, Y., Davies, G., & Coates, A. (2019). Bedaquiline kills persistent <i>Mycobacterium tuberculosis</i> with no disease relapse: an <i>in vivo</i> model of a potential cure. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(6), 1627-1633. doi:10.1093/jac/dkz052
Poor outcomes in recurrent tuberculosis: More than just drug resistance?
Cohen, D. B., Davies, G., Malwafu, W., Mangochi, H., Joekes, E., Greenwood, S., . . . Squire, S. B. (2019). Poor outcomes in recurrent tuberculosis: More than just drug resistance?. PLOS ONE, 14(5). doi:10.1371/journal.pone.0215855
Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis Reply
Velasquez, G. E., Brooks, M. B., Coit, J. M., Sanchez Garavito, E., Calderon, R. I., Jimenez, J., . . . Mitnick, C. D. (2019). Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis Reply. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 199(9), 1167-1168. doi:10.1164/rccm.201812-2281LE
NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis
Richardson, M., Kirkham, J., Dwan, K., Sloan, D. J., Davies, G., & Jorgensen, A. L. (2019). NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 23(3), 293-305. doi:10.5588/ijtld.18.0324
Intra-individual effects of food upon the pharmacokinetics of rifampicin and isoniazid
Requena-Mendez, A., Davies, G., Waterhouse, D., Ardrey, A., Jave, O., Llanet Lopez-Romero, S., . . . Moore, D. A. J. (2019). Intra-individual effects of food upon the pharmacokinetics of rifampicin and isoniazid. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(2), 416-424. doi:10.1093/jac/dky444
Association of variants within the <i>GST</i> and other genes with anti-tubercular agents related toxicity: a systematic review and meta-analysis
Richardson, M., Kirkham, J., Dwan, K., Sloan, D., Davies, G., & Jorgensen, A. (2019). Association of variants within the <i>GST</i> and other genes with anti-tubercular agents related toxicity: a systematic review and meta-analysis. doi:10.1101/515817
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis (vol 24, 1708, 2018)
Imperial, M. Z., Nahid, P., Phillips, P. P. J., Davies, G. R., Fielding, K., Hanna, D., . . . Savic, R. M. (2019). A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis (vol 24, 1708, 2018). NATURE MEDICINE, 25(1), 190. doi:10.1038/s41591-018-0294-1
Latent tuberculosis infection screening in HIV-infected patients: guidelines versus everyday practice in a UK HIV centre
Aston, S. J., Doherty, K., Black, B., & Davies, G. (2019). Latent tuberculosis infection screening in HIV-infected patients: guidelines versus everyday practice in a UK HIV centre. HIV MEDICINE, 20(1), E3-E4. doi:10.1111/hiv.12678
Model-Based Relationship between the Molecular Bacterial Load Assay and Time to Positivity in Liquid Culture
Svensson, R. J., Sabiiti, W., Kibiki, G. S., Ntinginya, N. E., Bhatt, N., Davies, G., . . . Simonsson, U. S. H. (2019). Model-Based Relationship between the Molecular Bacterial Load Assay and Time to Positivity in Liquid Culture. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(10). doi:10.1128/AAC.00652-19
2018
Evaluation of the efficacy of two methods for direct extraction of DNA from Mycobacterium tuberculosis sputum
Ndhlovu, V., Mandala, W., Sloan, D., Kamdolozi, M., Caws, M., & Davies, G. (n.d.). Evaluation of the efficacy of two methods for direct extraction of DNA from Mycobacterium tuberculosis sputum. The Journal of Infection in Developing Countries, 12(12), 1067-1072. doi:10.3855/jidc.10592
<i>CYP</i> genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis
Richardson, M., Kirkham, J., Dwan, K., Sloan, D. J., Davies, G., & Jorgensen, A. L. (2018). <i>CYP</i> genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis. SYSTEMATIC REVIEWS, 7. doi:10.1186/s13643-018-0861-z
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
Imperial, M. Z., Nahid, P., Phillips, P. P. J., Davies, G. R., Fielding, K., Hanna, D., . . . Savic, R. M. (2018). A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nature Medicine, 24(11), 1708-1715. doi:10.1038/s41591-018-0224-2
Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial
Velasquez, G. E., Brooks, M. B., Coit, J. M., Pertinez, H., Vasquez, D. V., Garavito, E. S., . . . Mitnick, C. D. (2018). Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine, 198(5), 657-666. doi:10.1164/rccm.201712-2524OC
Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis
Stott, K. E., Pertinez, H., Sturkenboom, M. G. G., Boeree, M. J., Aarnoutse, R., Ramachandran, G., . . . Davies, G. (2018). Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(9), 2305-2313. doi:10.1093/jac/dky152
Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation
Millard, J., Pertinez, H., Bonnett, L., Hodel, E. M., Dartois, V., Johnson, J. L., . . . Sloan, D. J. (2018). Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(7), 1755-1762. doi:10.1093/jac/dky096
Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent<i> Mycobacterium tuberculosis</i> in the Cornell Mouse Model
Liu, Y., Pertinez, H., Davies, G. R., Gillespie, S. H., Coates, A. R., & Hua, Y. (2018). Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent<i> Mycobacterium tuberculosis</i> in the Cornell Mouse Model. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(7). doi:10.1128/AAC.00190-18
HIV-Associated <i>Mycobacterium tuberculosis</i> Bloodstream Infection Is Underdiagnosed by Single Blood Culture
Barr, D. A., Kerkhoff, A. D., Schutz, C., Ward, A. M., Davies, G. R., Wilkinson, R. J., & Meintjes, G. (2018). HIV-Associated <i>Mycobacterium tuberculosis</i> Bloodstream Infection Is Underdiagnosed by Single Blood Culture. JOURNAL OF CLINICAL MICROBIOLOGY, 56(5). doi:10.1128/JCM.01914-17
Making up the difference: ensuring the bioequivalence of fixed-dose combinations for tuberculosis
Velasquez, G. E., Davies, G. R., & Mitnick, C. D. (2018). Making up the difference: ensuring the bioequivalence of fixed-dose combinations for tuberculosis. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 22(5), 473-474. doi:10.5588/ijtld.18.0210
Linezolid pharmacokinetics in multidrug resistant tuberculosis (MDR TB): a systematic review, meta-analysis and Monte Carlo simulation
Millard, J., Pertinez, H., Bonnett, L. J., Hodel, E., Dartois, V., Johnson, J. L., . . . Sloan, D. (2018). Linezolid pharmacokinetics in multidrug resistant tuberculosis (MDR TB): a systematic review, meta-analysis and Monte Carlo simulation. Journal of Antimicrobial Chemotherapy.
Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria
Liu, Y., Pertinez, H., Ortega-Muro, F., Alameda-Martin, L., Harrison, T., Davies, G., . . . Hu, Y. (2018). Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(3), 724-731. doi:10.1093/jac/dkx467
Quality of reporting of outcomes in phase III studies of pulmonary tuberculosis: a systematic review
Bonnett, L. J., Ken-Dror, G., & Davies, G. R. (2018). Quality of reporting of outcomes in phase III studies of pulmonary tuberculosis: a systematic review. TRIALS, 19. doi:10.1186/s13063-018-2522-x
2017
Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis (vol 61, e00038-17, 2017)
Peloquin, C. A., Velasquez, G. E., Lecca, L., Calderon, R. I., Coit, J., Milstein, M., . . . Daviesh, G. (2017). Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis (vol 61, e00038-17, 2017). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(9). doi:10.1128/AAC.01524-17
Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis
Peloquin, C. A., Velasquez, G. E., Lecca, L., Calderon, R. I., Coit, J., Milstein, M., . . . Davies, G. (2017). Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(8). doi:10.1128/AAC.00038-17
Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol)
Richardson, M. H., Kirkham, J., Dwan, K., Sloan, D., Davies, G., & Jorgensen, A. (2017). Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol). Systematic Reviews. doi:10.1186/s13643-017-0533-4
Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis model
de Knegt, G. J., Dickinson, L., Pertinez, H., Evangelopoulos, D., McHugh, T. D., Bakker-Woudenberg, I. A. J. M., . . . de Steenwinkel, J. E. M. (2017). Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis model. TUBERCULOSIS, 105, 113-118. doi:10.1016/j.tube.2017.05.002
Comparing the Efficacy of Drug Regimens for Pulmonary Tuberculosis: Meta-analysis of Endpoints in Early-Phase Clinical Trials
Bonnett, L. J., Ken-Dror, G., Koh, G., & Davies, G. (2017). Comparing the Efficacy of Drug Regimens for Pulmonary Tuberculosis: Meta-analysis of Endpoints in Early-Phase Clinical Trials. Clinical Infectious Diseases, 65(1), 46-54. doi:10.1093/cid/cix247
Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis
Sloan, D. J., McCallum, A. D., Schipani, A., Egan, D., Mwandumba, H. C., Ward, S. A., . . . Davies, G. R. (2017). Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(7). doi:10.1128/AAC.00210-17
TST positivity in household contacts of tuberculosis patients: a case-contact study in Malawi
Hector, J., Anderson, S. T., Banda, G., Kamdolozi, M., Jefferys, L. F., Shani, D., . . . Sloan, D. J. (2017). TST positivity in household contacts of tuberculosis patients: a case-contact study in Malawi. BMC INFECTIOUS DISEASES, 17. doi:10.1186/s12879-017-2348-2
The implications of model-informed drug discovery and development for tuberculosis.
Muliaditan, M., Davies, G. R., Simonsson, U. S. H., Gillespie, S. H., & Della Pasqua, O. (2017). The implications of model-informed drug discovery and development for tuberculosis. DRUG DISCOVERY TODAY, 22(3), 481-486. doi:10.1016/j.drudis.2016.09.004
2016
Methods for selecting regimen duration to prevent relapse in drug-susceptible and drug-resistant TB
Davies, G. R., & Wallis, R. S. (2016). Methods for selecting regimen duration to prevent relapse in drug-susceptible and drug-resistant TB. In INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE Vol. 20 (pp. S13-S17). doi:10.5588/ijtld.16.0231
Perceptions of Research Bronchoscopy in Malawian Adults with Pulmonary Tuberculosis: A Cross-Sectional Study
McCallum, A. D., Nyirenda, D., Lora, W., Khoo, S. H., Sloan, D. J., Mwandumba, H. C., . . . Davies, G. R. (2016). Perceptions of Research Bronchoscopy in Malawian Adults with Pulmonary Tuberculosis: A Cross-Sectional Study. PLOS ONE, 11(10). doi:10.1371/journal.pone.0165734
Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.
Milstein, M., Lecca, L., Peloquin, C., Mitchison, D., Seung, K., Pagano, M., . . . Mitnick, C. D. (2016). Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.. BMC infectious diseases, 16(1), 453. doi:10.1186/s12879-016-1790-x
Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model
Hu, Y., Pertinez, H., Ortega-Muro, F., Alameda-Martin, L., Liu, Y., Schipani, A., . . . Coates, A. (2016). Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(8), 4778-4785. doi:10.1128/AAC.02548-15
Optimising molecular diagnostic capacity for effective control of tuberculosis in high-burden settings
Sabiiti, W., Mtafya, B., Kuchaka, D., Azam, K., Viegas, S., Mdolo, A., . . . Biomarker, P. A. N. B. I. O. M. E. P. -A. (2016). Optimising molecular diagnostic capacity for effective control of tuberculosis in high-burden settings. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 20(8), 1004-1009. doi:10.5588/ijtld.15.0951
Serial image analysis of <i>Mycobacterium tuberculosis</i> colony growth reveals a persistent subpopulation in sputum during treatment of pulmonary TB
Barr, D. A., Kamdolozi, M., Nishihara, Y., Ndhlovu, V., Khonga, M., Davies, G. R., & Sloan, D. J. (2016). Serial image analysis of <i>Mycobacterium tuberculosis</i> colony growth reveals a persistent subpopulation in sputum during treatment of pulmonary TB. TUBERCULOSIS, 98, 110-115. doi:10.1016/j.tube.2016.03.001
A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children
Schipani, A., Pertinez, H., Mlota, R., Molyneux, E., Lopez, N., Dzinjalamala, F. K., . . . Davies, G. (2016). A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 81(4), 679-687. doi:10.1111/bcp.12848
Adequacy of Rifampin Absorption after Jejunostomy Tube Administration
Stott, K. E., Singh, B., Beadsworth, M. B. J., Vaudrey, K., Khoo, S. H., & Davies, G. (2016). Adequacy of Rifampin Absorption after Jejunostomy Tube Administration. PHARMACOTHERAPY, 36(4), E23-E25. doi:10.1002/phar.1730
Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults
Furin, J., Alirol, E., Allen, E., Fielding, K., Merle, C., Abubakar, I., . . . du Cros, R. (2016). Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 20(3), 290-294. doi:10.5588/ijtld.15.0490
2015
Quality of outcome reporting in phase II studies in pulmonary tuberculosis
Bonnett, L. J., & Davies, G. R. (2015). Quality of outcome reporting in phase II studies in pulmonary tuberculosis. TRIALS, 16. doi:10.1186/s13063-015-1050-1
Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi
van Oosterhout, J. J., Dzinjalamala, F. K., Dimba, A., Waterhouse, D., Davies, G., Zijlstra, E. E., . . . Ward, S. (2015). Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(10), 6175-6180. doi:10.1128/AAC.01193-15
An integrated model of care for neurological infections: the first six years of referrals to a specialist service at a university teaching hospital in Northwest England
Turtle, L., Jung, A., Beeching, N. J., Cocker, D., Davies, G. R., Nicolson, A., . . . Solomon, T. (2015). An integrated model of care for neurological infections: the first six years of referrals to a specialist service at a university teaching hospital in Northwest England. BMC INFECTIOUS DISEASES, 15. doi:10.1186/s12879-015-1109-3
Vitamin D deficiency in Malawian adults with pulmonary tuberculosis: risk factors and treatment outcomes
Sloan, D. J., Mwandumba, H. C., Kamdolozi, M., Shani, D., Chisale, B., Dutton, J., . . . Davies, G. R. (2015). Vitamin D deficiency in Malawian adults with pulmonary tuberculosis: risk factors and treatment outcomes. The International Journal of Tuberculosis and Lung Disease, 19(8), 904-911. doi:10.5588/ijtld.15.0071
Vitamin D deficiency in Malawian adults with pulmonary tuberculosis: risk factors and treatment outcomes
Sloan, D. J., Mwandumba, H. C., Kamdolozi, M., Shani, D., Chisale, B., Dutton, J., . . . Davies, G. R. (2015). Vitamin D deficiency in Malawian adults with pulmonary tuberculosis: risk factors and treatment outcomes. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 19(8), 904-911. doi:10.5588/ijtld.15.0071
Kinetics of <i>Mycobacterium tuberculosis</i>-specific IFN-γ responses and sputum bacillary clearance in HIV-infected adults during treatment of pulmonary tuberculosis
Mzinza, D. T., Sloan, D. J., Jambo, K. C., Shani, D., Kamdolozi, M., Wilkinson, K. A., . . . Mwandumba, H. C. (2015). Kinetics of <i>Mycobacterium tuberculosis</i>-specific IFN-γ responses and sputum bacillary clearance in HIV-infected adults during treatment of pulmonary tuberculosis. TUBERCULOSIS, 95(4), 463-469. doi:10.1016/j.tube.2015.05.009
Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis
Sloan, D. J., Mwandumba, H. C., Garton, N. J., Khoo, S. H., Butterworth, A. E., Allain, T. J., . . . Davies, G. R. (2015). Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis. Clinical Infectious Diseases, 61(1), 1-8. doi:10.1093/cid/civ195
Adaptive clinical trials in tuberculosis: applications, challenges and solutions
Davies, G. R., Phillips, P. P. J., & Jaki, T. (2015). Adaptive clinical trials in tuberculosis: applications, challenges and solutions. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 19(6), 626-634. doi:10.5588/ijtld.14.0988
Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol
Mlotha, R., Waterhouse, D., Dzinjalamala, F., Ardrey, A., Molyneux, E., Davies, G., & Ward, S. (2015). Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol. The Journal of Antimicrobial Chemotherapy, 70(6), 1798-1803. doi:10.1093/jac/dkv039
Reported outcomes in phase II studies of newly-diagnosed pulmonary tuberculosis
Bonnett, L. J., & Davies, G. (2015). Reported outcomes in phase II studies of newly-diagnosed pulmonary tuberculosis. TRIALS, 16. doi:10.1186/1745-6215-16-S1-P7
Reply to "Adequate Design of Pharmacokinetic-Pharmacodynamic Studies Will Help Optimize Tuberculosis Treatment for the Future"
Requena-Mendez, A., Davies, G., & Moore, D. A. J. (2015). Reply to "Adequate Design of Pharmacokinetic-Pharmacodynamic Studies Will Help Optimize Tuberculosis Treatment for the Future". ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(4), 2475. doi:10.1128/AAC.05182-14
<i>HspX</i> knock-out in <i>Mycobacterium tuberculosis</i> leads to shorter antibiotic treatment and lower relapse rate in a mouse model e A potential novel therapeutic target
Hu, Y., Liu, A., Menendez, M. C., Garcia, M. J., Oravcova, K., Gillespie, S. H., . . . Coates, A. R. M. (2015). <i>HspX</i> knock-out in <i>Mycobacterium tuberculosis</i> leads to shorter antibiotic treatment and lower relapse rate in a mouse model e A potential novel therapeutic target. TUBERCULOSIS, 95(1), 31-36. doi:10.1016/j.tube.2014.11.002
Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine
Schipani, A., Back, D., Owen, A., Davies, G., Khoo, S., & Siccardi, M. (2015). Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine. CLINICAL PHARMACOKINETICS, 54(1), 107-116. doi:10.1007/s40262-014-0184-8
2014
Effects of Dosage, Comorbidities, and Food on Isoniazid Pharmacokinetics in Peruvian Tuberculosis Patients
Requena-Mendez, A., Davies, G., Waterhouse, D., Ardrey, A., Jave, O., Llanet Lopez-Romero, S., . . . Moore, D. A. J. (2014). Effects of Dosage, Comorbidities, and Food on Isoniazid Pharmacokinetics in Peruvian Tuberculosis Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58(12), 7164-7170. doi:10.1128/AAC.03258-14
RISK FACTORS AND THERAPEUTIC IMPLICATIONS OF VITAMIN D DEFICIENCY IN MALAWIAN ADULTS WITH PULMONARY TUBERCULOSIS
Sloan, D. J., Guwende, C., Banda, G., Shani, D., Kamdolozi, M., Chisale, B., . . . Davies, G. R. (2014). RISK FACTORS AND THERAPEUTIC IMPLICATIONS OF VITAMIN D DEFICIENCY IN MALAWIAN ADULTS WITH PULMONARY TUBERCULOSIS. In THORAX Vol. 69 (pp. A42). doi:10.1136/thoraxjnl-2014-206260.81
Effects of Dosage, Comorbidities, and Food on Isoniazid Pharmacokinetics in Peruvian Tuberculosis Patients
Requena-Méndez, A., Davies, G., Waterhouse, D., Ardrey, A., Jave, O., López-Romero, S. L., . . . Moore, D. A. J. (2014). Effects of Dosage, Comorbidities, and Food on Isoniazid Pharmacokinetics in Peruvian Tuberculosis Patients. Antimicrobial Agents and Chemotherapy, 58(12), 7164-7170. doi:10.1128/AAC.03258-14
Pharmacologic Considerations in Use and Development of Antituberculosis Drugs
Davies, G. (2015). Pharmacologic Considerations in Use and Development of Antituberculosis Drugs. COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 5(1). doi:10.1101/cshperspect.a021170
Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated <i>Plasmodium falciparum</i> infection in Burkina Faso
Valea, I., Tinto, H., Coulibaly, M. T., Toe, L. C., Lindegardh, N., Tarning, J., . . . Ward, S. A. (2014). Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated <i>Plasmodium falciparum</i> infection in Burkina Faso. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(9), 2499-2507. doi:10.1093/jac/dku154
Clinical Tuberculosis
Davies, P. D. O., Gordon, S. B., & Davies, G. (Eds.) (n.d.). Clinical Tuberculosis. In . CRC Press. doi:10.1201/b16604
Pharmacokinetic Variability in TB Therapy: Associations With HIV and Effect On Outcome
Sloan, D. J., Schipani, A., Waterhouse, D., Stone, L., Mwandumba, H. C., Butterworth, A. E., . . . Davies, G. R. (2014). Pharmacokinetic Variability in TB Therapy: Associations With HIV and Effect On Outcome. Topics in Antiviral Medicine, 22(e-1), 55. Retrieved from https://www.iasusa.org/tam/april-2014
2013
Bridging the gap in the fight against tuberculosis.
Davies, G. R. (2013). Bridging the gap in the fight against tuberculosis.. Drug discovery today. Technologies, 10(3), e359-e364. doi:10.1016/j.ddtec.2012.04.007
New Drugs and Treatment Regimens
Sloan, D., Davies, G., & Khoo, S. (2013). New Drugs and Treatment Regimens. Current Respiratory Medicine Reviews, 9(3), 200-210. doi:10.2174/1573398x113099990017
Pharmacometrics: Opportunity for reducing disease burden in the developing world: The case of Africa
Pillai, G., Davies, G., Denti, P., Steimer, J. L., McIlleron, H., Zvada, S., . . . Holford, N. H. G. (2013). Pharmacometrics: Opportunity for reducing disease burden in the developing world: The case of Africa. CPT: Pharmacometrics and Systems Pharmacology, 2(9).
Opinion: the pharmacometrics of infectious disease.
Davies, G. R., Hope, W., & Khoo, S. (2013). Opinion: the pharmacometrics of infectious disease.. CPT: pharmacometrics & systems pharmacology, 2, e70. doi:10.1038/psp.2013.46
Pharmacometrics: opportunity for reducing disease burden in the developing world: the case of Africa.
Pillai, G., Davies, G., Denti, P., Steimer, J. -L., McIlleron, H., Zvada, S., . . . Holford, N. H. G. (2013). Pharmacometrics: opportunity for reducing disease burden in the developing world: the case of Africa.. CPT: pharmacometrics & systems pharmacology, 2, e69. doi:10.1038/psp.2013.45
Opinion: The Pharmacometrics of Infectious Disease
Davies, G. R., Hope, W., & Khoo, S. (2013). Opinion: The Pharmacometrics of Infectious Disease. CPT: Pharmacometrics & Systems Pharmacology, 2(8), 1-3. doi:10.1038/psp.2013.46
Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)
Ziganshina, L. E., Titarenko, A. F., & Davies, G. R. (2013). Fluoroquinolones for treating tuberculosis (presumed drug-sensitive). COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (6). doi:10.1002/14651858.CD004795.pub4
Recent advances in tuberculosis: New drugs and treatment regimens.
Sloan, D. J., Davies, G. R., & Khoo, S. H. (2013). Recent advances in tuberculosis: New drugs and treatment regimens.. Current respiratory medicine reviews, 9(3), 200-210. doi:10.2174/1573398x113099990017
Modelling Responses to Tuberculosis Treatment
Davies, G. R. (2013). Modelling Responses to Tuberculosis Treatment. In TUBERCULOSIS: LABORATORY DIAGNOSIS AND TREATMENT STRATEGIES (pp. 147-163). Retrieved from https://www.webofscience.com/
Intensive phase bacillary elimination predicts clinical outcome in HIV + and HIV- Malawian adults with smear positive pulmonary TB
Sloan, D., Mwandumba, H., Guwende, C., Chipungu, G., Butterworth, A., Dutton, J., . . . Davies, G. (2013). Intensive phase bacillary elimination predicts clinical outcome in HIV + and HIV- Malawian adults with smear positive pulmonary TB. Conference on Retroviruses and Opportunistic Infections, 1, 858.
New Drugs and Treatment Regimens for tuberculosis
Sloan, D. J., Davies, G. R., & Khoo, S. H. (2013). New Drugs and Treatment Regimens for tuberculosis. Current Respiratory Medicine Reviews, 9(3), 200-210.
Population Pharmacokinetics of Twice Daily Zidovudine in HIV-Infected Children and an assessment of ZDV exposure following WHO dosing guidelines
Dickinson, L., Fillekes, Q., Cressey, T. R., Chokephaibulkit, K., Davies, G. R., Musiime, V., . . . Walker, S. (2013). Population Pharmacokinetics of Twice Daily Zidovudine in HIV-Infected Children and an assessment of ZDV exposure following WHO dosing guidelines. In Reviews in Antiviral Therapy and Infectious Diseases Vol. 3 (pp. 45). Retrieved from http://regist2.virology-education.com/abstractbook/2013_3.pdf
Population pharmacokinetics of rifampicin in Malawian children
Schipani, A., Pertinez, H., Mlota, R., Lopez, N., Tembo, P., Ward, S., . . . Davies, G. (2013). Population pharmacokinetics of rifampicin in Malawian children. PAGE 2013, 1, I-12. Retrieved from http://www.page-meeting.org/default.asp?abstract=2782
Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies
Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., . . . Davies, G. (2013). Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 62(1), 60-66. doi:10.1097/QAI.0b013e3182737231
Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies
Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., . . . Davies, G. (2013). Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies. J Acquir Immune Defic Syndr, 62(1), 60-66. doi:10.1097/QAI.0b013e3182737231
The pharmacometrics of infectious diseases
Davies, G. R., Khoo, S. H., & Hope, W. (2013). The pharmacometrics of infectious diseases. CPT: Pharmacometrics and systems pharmacology, 2, e70. Retrieved from cpt:%20pharmacomet.%20syst.%20pharmacol.%202:%20e70;%20doi:10.1038/psp.2013.46
2012
Adjunctive rifampicin to reduce early mortality from <i>Staphylococcus aureus</i> bacteraemia (ARREST): study protocol for a randomised controlled trial
Thwaites, G., Auckland, C., Barlow, G., Cunningham, R., Davies, G., Edgeworth, J., . . . Walker, A. S. (2012). Adjunctive rifampicin to reduce early mortality from <i>Staphylococcus aureus</i> bacteraemia (ARREST): study protocol for a randomised controlled trial. TRIALS, 13. doi:10.1186/1745-6215-13-241
Simultaneous population pharmacokinetic modelling of darunavir and ritonavir Once daily in HIV-infected patients: evaluation of lower ritonavir dose
Dickinson, L., Jackson, A., Garvey, L., Watson, V., Khoo, S., Boffito, M., . . . Back, D. (2012). Simultaneous population pharmacokinetic modelling of darunavir and ritonavir Once daily in HIV-infected patients: evaluation of lower ritonavir dose. Journal of the International AIDS Society, 15(4).
Estimation of the effect of <i>SLCO1B1</i> polymorphisms on lopinavir plasma concentration in HIV-infected adults
Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of <i>SLCO1B1</i> polymorphisms on lopinavir plasma concentration in HIV-infected adults. ANTIVIRAL THERAPY, 17(5), 861-868. doi:10.3851/IMP2095
Optimizing Outpatient Serial Sputum Colony Counting for Studies of Tuberculosis Treatment in Resource-Poor Settings
Sloan, D. J., Corbett, E. L., Butterworth, A. E., Mwandumba, H. C., Khoo, S. H., Mdolo, A., . . . Davies, G. R. (2012). Optimizing Outpatient Serial Sputum Colony Counting for Studies of Tuberculosis Treatment in Resource-Poor Settings. JOURNAL OF CLINICAL MICROBIOLOGY, 50(7), 2315-2320. doi:10.1128/JCM.00043-12
In routine UK hospital practice T-SPOT.TB™ is useful in some patients with a modest pre-test probability of active tuberculosis
Turtle, L., Kemp, T., Davies, G. R., Squire, S. B., Beeching, N. J., & Beadsworth, M. B. J. (2012). In routine UK hospital practice T-SPOT.TB™ is useful in some patients with a modest pre-test probability of active tuberculosis. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 23(4), 363-367. doi:10.1016/j.ejim.2012.01.002
In routine UK hospital practice T-SPOT.TB™ is useful in some patients with a modest pre-test probability of active tuberculosis.
Turtle, L., Kemp, T., Davies, G. R., Squire, S. B., Beeching, N. J., & Beadsworth, M. B. J. (2012). In routine UK hospital practice T-SPOT.TB™ is useful in some patients with a modest pre-test probability of active tuberculosis.. European journal of internal medicine, 23(4), 363-367. doi:10.1016/j.ejim.2012.01.002
The chemotherapy of tuberculosis: past, present and future
Mitchison, D., & Davies, G. (2012). The chemotherapy of tuberculosis: past, present and future. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 16(6), 724-732. doi:10.5588/ijtld.12.0083
Pharmacokinetics of Rifampin in Peruvian Tuberculosis Patients with and without Comorbid Diabetes or HIV
Requena-Mendez, A., Davies, G., Ardrey, A., Jave, O., Lopez-Romero, S. L., Ward, S. A., & Moore, D. A. J. (2012). Pharmacokinetics of Rifampin in Peruvian Tuberculosis Patients with and without Comorbid Diabetes or HIV. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(5), 2357-2363. doi:10.1128/AAC.06059-11
'I Told You So' Said the Surgeon to the Physician!
Chrdle, A., Folb, J., Davies, G., Mehra, S., Rigdway, D., & Beadsworth, M. B. J. (2012). 'I Told You So' Said the Surgeon to the Physician!. Federation of Infection Societies 2012, -. Retrieved from http://www.hisconference.org.uk/documents/Programmepagesfromv6handbook.pdf
Bacillary Elimination Rates, Persister Phenotypes and Clinical Outcomes in a Longitudinal Study of TB Treatment in Malawi
Sloan, D. J., Mwandumba, H. C., Corbett, E. L., Butterworth, A. E., Chipungu, G., Heyderman, R. S., . . . Davies, G. R. (2012). Bacillary Elimination Rates, Persister Phenotypes and Clinical Outcomes in a Longitudinal Study of TB Treatment in Malawi. Keystone Symposium : Drug Resistance and Persistence in Tuberculosis Kampala Uganda May 2012, -.
Clinical experience with Tspot.TB™ for diagnosis of tuberculosis in HIV negative and HIV positive patients
Turtle, L., Kemp, T., Davies, G. R., Beeching, N. J., & Beadsworth, M. B. J. (2012). Clinical experience with Tspot.TB™ for diagnosis of tuberculosis in HIV negative and HIV positive patients. Eur J Int Med, 23(4), 363-367.
Effect of dose size and food on pharmacokinetics of isoniazid in peruvian TB patients
Requena-Mendez, A., Davies, G. R., Ardrey, A., Jave, O., Ward, S., & Moore, D. (2012). Effect of dose size and food on pharmacokinetics of isoniazid in peruvian TB patients. 5th International Workshop on the Clinical pharmacology of anti-tuberculosis drugs San Francisco 2012, -.
Effect of limit of detection on analyses of bacteriological biomarkers in TB clinical trials
Davies, G. R., Martineau, A., & Lienhardt, C. (2012). Effect of limit of detection on analyses of bacteriological biomarkers in TB clinical trials. 5th International Workshop on the Clinical pharmacology of anti-tuberculosis drugs San Francisco 2012, -.
Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults
Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. Antiviral Therapy, 17(5), 861-868.
Pharmacokinetic-pharmacodynamic modelling of tuberculosis treatment response in Malawian adults with smear positive pulmonary tuberculosis
Sloan, D. J., Mwandumba, H. C., Corbett, E. L., Butterworth, A. E., Chipungu, G., Heyderman, R. S., . . . Davies, G. R. (2012). Pharmacokinetic-pharmacodynamic modelling of tuberculosis treatment response in Malawian adults with smear positive pulmonary tuberculosis. International Workshop on the Clinical pharmacology of anti-tuberculosis drugs San Francisco 2012, -.
Predicting ritonavir-boosted saquinavir exposure in HIV-infected patients aged 2-15 years using adult data as prior information
Dickinson, L., Levi, M., Davies, G., Khoo, S., Pozniak, A., Boffito, M., & Back, D. (2012). Predicting ritonavir-boosted saquinavir exposure in HIV-infected patients aged 2-15 years using adult data as prior information. In 13th International Workshop on Clinical Pharmacology of HIV Therapy Vol. -.
Rifampicin pharmacokinetics in Peruvian tuberculosis patients with and without co-morbid diabetes or HIV
Requena-Menendez, A., Davies, G. R., Ardey, A., Jave, O., López-Romero, S. L., Ward, S. A., & Moore, D. A. J. (2012). Rifampicin pharmacokinetics in Peruvian tuberculosis patients with and without co-morbid diabetes or HIV. Antimicrobial Agents & Chemotherapy, 56(5), 2357-2363.
2011
Serial Sputum Colony Counting in Drug Development
Sloan, D., & Davies, G. (2011). Serial Sputum Colony Counting in Drug Development. In ANTITUBERCULOSIS CHEMOTHERAPY (Vol. 40, pp. 227-234). Retrieved from https://www.webofscience.com/
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals
Schipani, A., Wyen, C., Mahungu, T., Hendra, H., Egan, D., Siccardi, M., . . . Back, D. J. (2011). Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66(6), 1332-1339. doi:10.1093/jac/dkr087
Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies
Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies. Antimicrobial Agents and Chemotherapy, 55(6), 2775-2782. doi:10.1128/aac.00887-10
Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies
Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(6), 2775-2782. doi:10.1128/AAC.00887-10
High-dose vitamin D<sub>3</sub> during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial
Martineau, A. R., Timms, P. M., Bothamley, G. H., Hanifa, Y., Islam, K., Claxton, A. P., . . . Griffiths, C. J. (2011). High-dose vitamin D<sub>3</sub> during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. LANCET, 377(9761), 242-250. doi:10.1016/S0140-6736(10)61889-2
Integrating Pharmacogenetics and Population Pharmacokinetic Analysis: Simulating the Impact of CYP2B6 516G>T for 400 mg Once-daily Nevirapine Dosing.
Schipani, A., Mahungu, T. W., Wyen, C., Esser, S., Brockmeyer, N., Khoo, S., . . . Back, D. (2011). Integrating Pharmacogenetics and Population Pharmacokinetic Analysis: Simulating the Impact of CYP2B6 516G>T for 400 mg Once-daily Nevirapine Dosing..
Population Pharmacokinetic Modelling of Plasma and Intracellular Once Daily Ritonavir-Boosted Darunavir in HIV-Infected Patients (Abstract O_12))
Dickinson, L., Jackson, A., Garvey, L., Watson, V., Khoo, S., Winston, A., . . . Back, D. (2011). Population Pharmacokinetic Modelling of Plasma and Intracellular Once Daily Ritonavir-Boosted Darunavir in HIV-Infected Patients (Abstract O_12)). Reviews in Antiviral Therapy and Infectious Diseases, 3, 13. Retrieved from http://regist2.virology-education.com/abstractbook/2011_3.pdf
Sequential population pharmacokinetic modelling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies
Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential population pharmacokinetic modelling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies. Antimicrobial Agents & Chemotherapy.
2010
Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance
Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(12), 5242-5250. doi:10.1128/AAC.00781-10
Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance
Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. Antimicrobial Agents and Chemotherapy, 54(12), 5242-5250. doi:10.1128/aac.00781-10
Insufficient Evidence for Chest CT Scan in TB Outbreak Investigation
Joekes, E., Davies, G., Mwandumba, H. C., & Squire, S. B. (2010). Insufficient Evidence for Chest CT Scan in TB Outbreak Investigation. CHEST, 138(1), 234-235. doi:10.1378/chest.10-0077
Early clinical development of anti-tuberculosis drugs: Science, statistics and sterilizing activity
Davies, G. R. (2010). Early clinical development of anti-tuberculosis drugs: Science, statistics and sterilizing activity. TUBERCULOSIS, 90(3), 171-176. doi:10.1016/j.tube.2010.03.007
Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: challenges and opportunities
Lienhardt, C., & Davies, G. (2010). Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: challenges and opportunities. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 14(5), 528-537. Retrieved from https://www.webofscience.com/
Biomarkers for tuberculosis disease activity, cure, and relapse
Phillips, P. P. J., Davies, G. R., & Mitchison, D. A. (2010). Biomarkers for tuberculosis disease activity, cure, and relapse. LANCET INFECTIOUS DISEASES, 10(2), 69-70. doi:10.1016/S1473-3099(09)70256-7
A Population Pharmacokinetic Model Illustrates an Association between a Pregnane-X Receptor Polymorphism and Boosted Atazanavir Clearance
Schipani, A., Siccardi, M., Boffito, M., D'Avolio, A., Bonora, S., Davies, G., . . . Owen, A. (2010). A Population Pharmacokinetic Model Illustrates an Association between a Pregnane-X Receptor Polymorphism and Boosted Atazanavir Clearance. Conference on Retroviruses and Opportunistic Infections, 618. Retrieved from http://www.retroconference.org/2010/Abstracts/39338.htm
A novel application of population pharmacokinetic analysis : simulating nevirapine dose adjustment according to CYP2B6 516G>T polymorphism
Schipani, A., Mahungu, T. W., Wyen, C., Esser, S., Brockmeyer, N. H., Khoo, S. H., . . . Back, D. J. (2010). A novel application of population pharmacokinetic analysis : simulating nevirapine dose adjustment according to CYP2B6 516G>T polymorphism. 11th Workshop on Clinical Pharmacology of HIV drugs, 20. Retrieved from http://regist2.virology-education.com/abstractbook/2010_2.pdf
Integrating Pharmacogenetics and Population Pharmacokinetic Analysis: Simulating the Impact of CYP2B6 516G>T for 400 mg Once-daily Nevirapine Dosing
Schipani, A., Mahungu, T. W., Wyen, C., Esser, S., Brockmeyer, N., Khoo, S., . . . Back, D. (2010). Integrating Pharmacogenetics and Population Pharmacokinetic Analysis: Simulating the Impact of CYP2B6 516G>T for 400 mg Once-daily Nevirapine Dosing. Conference on Retroviruses and Opportunistic Infections, 601. Retrieved from http://www.retroconference.org/2010/Abstracts/38775.htm
Modelling response to tuberculosis therapy
Davies, G. R. (2010). Modelling response to tuberculosis therapy. In T. D. McHugh (Ed.), Tuberculosis: progress in diagnosis & treatment (pp. 000). Wallingford, Oxford: CABI.
Population Pharmacokinetic Modelling of Once Daily Ritonavir-Boosted Darunavir in HIV-Infected Patients
Dickinson, L., Jackson, A., Garvey, L., Watson, V., Khoo, S., Winston, A., . . . Back, D. (2010). Population Pharmacokinetic Modelling of Once Daily Ritonavir-Boosted Darunavir in HIV-Infected Patients. Journal of the International AIDS Society, 13(S4), P184.
Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance
Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrobial Agents & Chemotherapy, 54(12), 5242-5250.
Population pharmacokinetics of pyrazinamide in healthy volunteers and tuberculosis patients in Thailand
Davies, G. R., Cheirakul, N., Saguenwong, N., Chaiprasert, A., Chuchuttaworn, C., Eompokalap, B., . . . Khoo, S. (2010). Population pharmacokinetics of pyrazinamide in healthy volunteers and tuberculosis patients in Thailand. 3rd Int Workshop on TB-PK, P_13. Retrieved from http://regist2.virology-education.com/
Serial sputum colony counting
Davies, G. R. (2010). Serial sputum colony counting. In P. R. Donald, & P. van Helden (Eds.), Antituberculosis Chemotherapy (pp. 000). Basel: Karger.
2009
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., . . . Aarons, L. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. Journal of Antimicrobial Chemotherapy, 63(6), 1233-1243. doi:10.1093/jac/dkp102
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., . . . Aarons, L. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 63(6), 1233-1243. doi:10.1093/jac/dkp102
Pharmacokinetics of High-Dose Oseltamivir in Healthy Volunteers
Wattanagoon, Y., Stepniewska, K., Lindegardh, N., Pukrittayakamee, S., Silachamroon, U., Piyaphanee, W., . . . White, N. J. (2009). Pharmacokinetics of High-Dose Oseltamivir in Healthy Volunteers. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 53(3), 945-952. doi:10.1128/AAC.00588-08
Assessment of the Efficacy of New Anti-Tuberculosis Drugs.
Mitchison, D. A., & Davies, G. R. (2008). Assessment of the Efficacy of New Anti-Tuberculosis Drugs.. The open infectious diseases journal, 2, 59-76. doi:10.2174/1874279300802010059
2008
Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs
Davies, G. R., & Nuermberger, E. L. (2008). Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. TUBERCULOSIS, 88, S65-S74. doi:10.1016/S1472-9792(08)70037-4
Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs.
Davies, G. R., & Nuermberger, E. L. (2008). Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs.. Tuberculosis (Edinburgh, Scotland), 88 Suppl 1, S65-S74. doi:10.1016/s1472-9792(08)70037-4
Doubts about DOTS - It's too soon to say that direct observation of short courses of tuberculosis treatment is failing
Davies, G. R., & Squire, S. B. (2008). Doubts about DOTS - It's too soon to say that direct observation of short courses of tuberculosis treatment is failing. BMJ-BRITISH MEDICAL JOURNAL, 336(7642), 457-458. doi:10.1136/bmj.39464.485208.80
A Factorial Study of the Effect of HIV, TB, and Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Anti-TB Drugs
Davies, G., Cheirakul, N., Saguenwong, N., Chaiprasert, A., Chuchuttaworn, C., Eompokalap, B., . . . Khoo, S. (2008). A Factorial Study of the Effect of HIV, TB, and Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Anti-TB Drugs. Conference on Retroviruses and Opportunistic Infections, O-1005. Retrieved from http://www.retroconference.org/2008/Abstracts/31198.htm
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis
Rustomjee, R., Lienhardt, C., Kanyok, T., Davies, G. R., Levin, J., Mthiyane, T., . . . Mitchison, D. A. (2008). A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 12(2), 128-138. Retrieved from https://www.webofscience.com/
2007
Rifabutin for treating pulmonary tuberculosis
Davies, G., Cerri, S., & Richeldi, L. (2007). Rifabutin for treating pulmonary tuberculosis. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (4). doi:10.1002/14651858.CD005159.pub2
A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin
Hartkoorn, R. C., Khoo, S., Back, D. J., Tjia, J. F., Waitt, C. J., Chaponda, M., . . . Ward, S. A. (2007). A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 857(1), 76-82. doi:10.1016/j.jchromb.2007.07.005
Biomarkers and surrogate end points in clinical trials of tuberculosis treatment
Davies, G. R., Phillips, P. P. J., & Nunn, A. J. (2007). Biomarkers and surrogate end points in clinical trials of tuberculosis treatment. JOURNAL OF INFECTIOUS DISEASES, 196(4), 648-649. doi:10.1086/519744
Isoniazid activity is terminated by bacterial persistence
Mitchison, D. A., Jindani, A., Davies, G. R., & Sirgel, F. (2007). Isoniazid activity is terminated by bacterial persistence. JOURNAL OF INFECTIOUS DISEASES, 195(12), 1871-1872. doi:10.1086/518046
Importance of collection tube during clinical studies of oseltamivir
Lindegardh, N., Davies, G. R., Hien, T. T., Farrar, J., Singhasivanon, P., Day, N. P. J., & White, N. J. (2007). Importance of collection tube during clinical studies of oseltamivir. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 51(5), 1835-1836. doi:10.1128/AAC.01534-06
Evaluation of new antituberculosis drugs in mouse models
Davies, G. R., Pym, A. S., & Mitchison, D. A. (2007). Evaluation of new antituberculosis drugs in mouse models. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 51(1), 403. doi:10.1128/AAC.01246-06
2006
Mixture analysis of tuberculin survey data from northern Malawi and critique of the method
Davies, G. R., Fine, P. E., & Vynnycky, E. (2006). Mixture analysis of tuberculin survey data from northern Malawi and critique of the method. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 10(9), 1023-1029. Retrieved from https://www.webofscience.com/
Optimal sampling strategies for early pharmacodynamic measures in tuberculosis
Davies, G. R., Khoo, S. H., & Aarons, L. J. (2006). Optimal sampling strategies for early pharmacodynamic measures in tuberculosis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 58(3), 594-600. doi:10.1093/jac/dkl272
Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases
Lindegardh, N., Davies, G. R., Hien, T. T., Farrar, J., Singhasivanon, P., Day, N. P. J., & White, N. J. (2006). Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 50(9), 3197-3199. doi:10.1128/AAC.00500-06
Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment
Davies, G. R., Brindle, R., Khoo, S. H., & Aarons, L. J. (2006). Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 50(9), 3154-3156. doi:10.1128/AAC.00774-05
2003
Sales of over-the-counter remedies as an early warning system for winter bed crises
Davies, G. R., & Finch, R. G. (2003). Sales of over-the-counter remedies as an early warning system for winter bed crises. CLINICAL MICROBIOLOGY AND INFECTION, 9(8), 858-863. doi:10.1046/j.1469-0691.2003.00693.x
2002
Loss of cytomegalovirus-specific immunological memory in a patient with thymoma
Huissoon, A. P., Davies, G., Cox, R. A., Sloper, C. M. L., Thomson, B. J., & Robins, R. A. (2002). Loss of cytomegalovirus-specific immunological memory in a patient with thymoma. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 129(2), 297-301. doi:10.1046/j.1365-2249.2002.01923.x
Successful conservative management of splenic rupture in vivax malaria
Davies, G. R., & Venkatesan, P. (2002). Successful conservative management of splenic rupture in vivax malaria. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 96(2), 149-150. doi:10.1016/S0035-9203(02)90285-3
2001
Fever of unknown origin
Davies, G. R., & Finch, R. G. (2001). Fever of unknown origin. CLINICAL MEDICINE, 1(3), 177-179. doi:10.7861/clinmedicine.1-3-177
1999
Who fails to complete tuberculosis treatment? Temporal trends and risk factors for treatment interruption in a community-based directly observed therapy programme in a rural district of South Africa
Connolly, C., Davies, G. R., & Wilkinson, D. (1999). Who fails to complete tuberculosis treatment? Temporal trends and risk factors for treatment interruption in a community-based directly observed therapy programme in a rural district of South Africa. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 3(12), 1081-1087. Retrieved from https://www.webofscience.com/
Twice-weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa
Davies, G. R., Connolly, C., Sturm, A. W., McAdam, K. P. W. J., & Wilkinson, D. (1999). Twice-weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa. AIDS, 13(7), 811-817. doi:10.1097/00002030-199905070-00010
Emergence of multidrug-resistant tuberculosis in a community-based directly observed treatment programme in rural South Africa
Davies, G. R., Pillay, M., Sturm, A. W., & Wilkinson, D. (1999). Emergence of multidrug-resistant tuberculosis in a community-based directly observed treatment programme in rural South Africa. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 3(9), 799-804. Retrieved from https://www.webofscience.com/
1998
Impact of the human immunodeficiency virus epidemic on mortality among adults with tuberculosis in rural South Africa, 1991-1995
Connolly, C., Davies, G. R., & Wilkinson, D. (1998). Impact of the human immunodeficiency virus epidemic on mortality among adults with tuberculosis in rural South Africa, 1991-1995. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2(11), 919-925. Retrieved from https://www.webofscience.com/
Pediatric tuberculosis in rural South Africa - Value of directly observed therapy
Wilkinson, D., & Davies, G. R. (1998). Pediatric tuberculosis in rural South Africa - Value of directly observed therapy. JOURNAL OF TROPICAL PEDIATRICS, 44(5), 266-269. doi:10.1093/tropej/44.5.266
1997
The increasing burden of tuberculosis in rural South Africa - Impact of the HIV epidemic
Wilkinson, D., & Davies, G. R. (1997). The increasing burden of tuberculosis in rural South Africa - Impact of the HIV epidemic. SOUTH AFRICAN MEDICAL JOURNAL, 87(4), 447-450. Retrieved from https://www.webofscience.com/
Coping with Africa's increasing tuberculosis burden: Are community supervisors an essential component of the DOT strategy?
Wilkinson, D., & Davies, G. R. (1997). Coping with Africa's increasing tuberculosis burden: Are community supervisors an essential component of the DOT strategy?. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2(7), 700-704. doi:10.1046/j.1365-3156.1997.d01-358.x
Efficacy of twice weekly treatment for tuberculosis given under direct observation in Africa
Wilkinson, D., Anderson, E., Davies, G. R., Sturm, A. W., & McAdam, K. P. W. J. (1997). Efficacy of twice weekly treatment for tuberculosis given under direct observation in Africa. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 91(1), 87-89. doi:10.1016/S0035-9203(97)90407-7
Molecular epidemiology and transmission dynamics of Mycobacterium tuberculosis in rural Africa
Wilkinson, D., Pillay, M., Crump, J., Lombard, C., Davies, G. R., & Sturm, A. W. (1997). Molecular epidemiology and transmission dynamics of Mycobacterium tuberculosis in rural Africa. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2(8), 747-753. doi:10.1046/j.1365-3156.1997.d01-386.x
1996
Directly observed therapy for tuberculosis in rural South Africa, 1991 through 1994
Wilkinson, D., Davies, G. R., & Connolly, C. (1996). Directly observed therapy for tuberculosis in rural South Africa, 1991 through 1994. AMERICAN JOURNAL OF PUBLIC HEALTH, 86(8), 1094-1097. doi:10.2105/AJPH.86.8_Pt_1.1094
HIV and tuberculosis
Davies, G. R., Wilkinson, D., & Colvin, M. (1996). HIV and tuberculosis. SOUTH AFRICAN MEDICAL JOURNAL, 86(1), 91. Retrieved from https://www.webofscience.com/
Resistance to antituberculosis drugs in rural South Africa: Rates, patterns, risks, and transmission dynamics
Wilkinson, D., Pillay, M., Davies, G. R., & Sturm, A. W. (1996). Resistance to antituberculosis drugs in rural South Africa: Rates, patterns, risks, and transmission dynamics. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 90(6), 692-695. doi:10.1016/S0035-9203(96)90440-X